57,99 €
2,37 % gestern
L&S, 8. Oktober, 22:54 Uhr
ISIN
US2521311074
Symbol
DXCM
Berichte

DexCom, Inc. Aktie News

Positiv
Seeking Alpha
3 Tage alt
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% gross margin, and 21% operating margin, supported by recurring sensor sales and innovation. Stelo opens a new market, providing a gateway to the G7 ecosystem and offering a scalable, user-friendly p...
Neutral
Business Wire
7 Tage alt
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to ...
Neutral
GlobeNewsWire
8 Tage alt
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Negativ
The Motley Fool
15 Tage alt
Medical device specialist DexCom (DXCM -0.10%) has encountered significant headwinds since last year. The company's financial results in 2024 weren't nearly as strong as the market had expected, and over the past eight months, it has faced the threat of tariffs that could harm its margins and bottom line.
Neutral
Seeking Alpha
19 Tage alt
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Neutral
PRNewsWire
19 Tage alt
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Neutral
Business Wire
24 Tage alt
VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference. “Each year, EASD provides a high-profile op...
Positiv
MarketBeat
24 Tage alt
When it comes to identifying target stocks for investment, compelling prospects may include companies that are undervalued and, simultaneously, expected to appreciate in the future.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen